1LumiraDx, Stirling, UK; 2Diagnostic Clinic of Longview, Longview, TX, USA; 3New Medical Healthcare, Wichita, KS, USA; 4Velocity Clinical Research, Banning, CA, USA
Fibrin degradation product D-dimer can be a valuable indicator for venous thromboembolism (VTE). Use of D-dimer testing in primary care settings can be limited by restricted access to laboratory services. This performance evaluation compares a quantitative, point-of-care D-dimer assay (LumiraDx D-Dimer Test) with a reference laboratory-based D-dimer assay.
Plasma samples from patients presenting to secondary care in the UK, USA and Germany were
analysed centrally using the LumiraDx D-Dimer Test and the bioMérieux VIDAS D-Dimer Exclusion II immunoassay™. Method comparison used Passing-Bablok regression analysis with pre-specified equivalence criteria of r≥0.9 and slope of 0.9–1.1. An equivalency study compared fingerstick, venous blood (VB) and plasma samples from the same subject, on the LumiraDx D-Dimer Test from patients presenting to healthcare providers, conducted under the NOVEL-3 study (NCT04375982). Measurements obtained from fingerstick and VB samples were compared with results from plasma samples, using Deming regression. The healthy reference range was determined using plasma samples of healthy volunteers, collected by commercial suppliers in Germany and the USA, which were analysed centrally using the LumiraDx D-Dimer Test and the reference test.
The LumiraDx D-Dimer Test demonstrated equivalence to the bioMérieux VIDAS D-Dimer Exclusion II immunoassay™ for plasma samples (r=0.923, slope of 1.016, n=1767). There was good agreement between fingerstick/VB samples and plasma samples (r=0.980–0.986, n=93) measured using the LumiraDx D-Dimer Test. The healthy reference range 90% percentile for D-dimer was calculated as 533 μg/L fibrinogen equivalent units (FEU). Overall error rates were 1.8% and the test was reported as easy to use by the operators.
The quantitative LumiraDx D-Dimer Test can accurately measure D-dimer levels in a range of
blood sample types, including fingerstick samples, which could improve assessment of VTE cases in community and hospital near-patient settings.
LumiraDx UK Ltd: Unit 1, Block 5, Dumyat Business Park, Bond Street, Alloa, FK10 2PB, UK
Copyright © 2020 LumiraDx UK LTD. All rights reserved worldwide.
Content should be used for the use of the LumiraDx products only and in line with instructions provided. You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other form of electronic retrieval system other than for the purpose of use of the LumiraDx Instrument or LumiraDx Test Strips. Information provided is subject to change without notice.
LumiraDx and Flame logo are trademarks of LumiraDx International LTD. Full details of these and other registrations of LumiraDx can be found at lumiradx.com/IP. All other trademarks are the property of their respective owners.
Supporting healthier lives, for individuals, communities and wider society.
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.